As 2020 gets underway, many companies are formalising their pipelines and priorities for the year ahead. But with this often comes the realisation of pharmaceutical development challenges that need to be resolved. Crystec are in the business of overcoming such challenges through crystal and particle engineering, using supercritical fluid based technologies. Here are some of the areas where our mSAS® (modified Supercritical Anti-Solvent) platform can be of help.
Polymorphism is a major concern for the pharmaceutical industry. Everything from efficacy to regulatory applications and intellectual property can be affected by a lack of polymorphic control over an API.
The quality of an inhalable formulation is judged on three key properties:
- Emitted Dose (ED): the amount of formulation which leaves the inhaler/device
- Fine Particle Fraction (FPF): the percentage of drug which reaches and stays in…